In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a ...

In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences Corporation's (NASDAQ:EXAS) future prospects. Exact Sciences Corporation provides ...

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch. Vandana Singh Rivian Automotive, Rocket Lab And ...

Get prepared with the key expectations. Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ...